Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Teva Pharmaceutical Industries Limited (TEVA)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
8.450.00 (0.00%)
At close: 04:00PM EDT
8.50 +0.05 (+0.59%)
After hours: 07:45PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close8.45
Open8.43
Bid8.48 x 4000
Ask8.50 x 1100
Day's Range8.26 - 8.50
52 Week Range7.23 - 11.55
Volume5,328,323
Avg. Volume9,047,208
Market Cap9.4B
Beta (5Y Monthly)1.18
PE Ratio (TTM)N/A
EPS (TTM)-0.56
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateNov 27, 2017
1y Target Est10.17
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
48% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for TEVA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Teva Pharmaceutical Industries
    Analyst Report: Teva Pharmaceutical Industries LimitedBased in Israel, Teva is one of the world’s largest generic drug manufacturers, with over 3,500 products marketed in over 60 countries. While a majority of its revenue is attributed to prescription generic drugs, Teva develops and markets its own branded specialty and biopharmaceutical products, primarily in the U.S. and in Europe. The company’s branded portfolio generates one fifth of total revenue and consists of patented therapies targeting central nervous system conditions (Austedo, Ajovy, Copaxone), oncology (Bendeka/Treanda), and respiratory conditions (ProAir, Qvar). While global competition has facilitated the commodification of small-molecule generic drugs, Teva’s portfolio rationalization has resulted in less overall price erosion versus peers.
    Rating
    Fair Value
    Economic Moat
    21 days agoMorningstar
View more
  • Business Wire

    Teva Presents New Long-Term AUSTEDO® (deutetrabenazine) Tablets Data at 2022 American Psychiatric Association Annual Meeting

    TEL AVIV, Israel & PARSIPPANY, N.J., May 23, 2022--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new efficacy and safety data from a 3-year open-label extension (OLE) study on AUSTEDO® (deutetrabenazine) tablets in postmenopausal women with tardive dyskinesia (TD). These data will be presented at the 2022 American Psychiatric Association (APA) Annual Meeting, held May 21-25 in New Orleans and online June 7-10. In addition, ne

  • Benzinga

    Teva Pharmaceutical Shares Real-World Data Of ProAir Digihaler In Asthma Patients

    Teva Pharmaceutical Industries Ltd (NYSE: TEVA) announced new study findings based on newly established clinical thresholds on short-acting beta-agonist (SABA) use and real-world usage of ProAir Digihaler (albuterol sulfate) inhalation powder. ProAir Digihaler is a breath-actuated, digital SABA inhaler with built-in flow sensors that detect, record, and store objective data. 89% (319/359) of patients met the consensus threshold of SABA reliever medication use, and 72% (260/359) met the threshold

  • Business Wire

    United Kingdom first to grant licence for Teva’s ophthalmology biosimilar Ongavia (ranibizumab)▼

    AMSTERDAM, May 17, 2022--Teva Pharmaceutical Industries Ltd welcomes the UK Medicines & Healthcare Regulatory Agency (MHRA) decision to grant a licence for Ongavia®, a biosimilar to Lucentis® (ranibizumab ), an eye injection. The United Kingdom is the first country in Europe to authorize commercialization of Ongavia® for the treatment of neovascular (wet) age-related macular degeneration ("AMD"). Ongavia® is also licenced for: the treatment of visual impairment due to diabetic macular oedema (DM

Advertisement
Advertisement